Top 5 Stocks Under $5 That Could Triple

4. Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is on our list of the top 10 stocks under $5 that could triple.

As of March 17, 2026, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) remains a preferred choice among analysts, with Wedbush increasing the price target to $14 from $13 and reiterating an “Outperform” rating on the company’s shares. The firm reflected optimism surrounding the company’s clinical pipeline and upcoming catalysts.

As its focus remains on precision oncology, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)’s recent progress in the silevertinib program has supported the company’s share price performance.

Wedbush analysts noted that, in December 2025,  the company had already reported preliminary Phase 2 data on silevertinib in NSCLC patients with uncommon EGFR mutations. The program is moving forward, and further data readouts are expected in the coming months, which remains a key catalyst.

On March 16, 2026, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported financial results for the fourth quarter and full year ended December 31, 2025. The company cited its 60% objective response rate, 86% CNS ORR, and 91% disease control rate from the previously released Phase 2 data, as well as the upcoming developments, which include the future data presentations and the initiation of a randomized Phase 2 GBM trial in Q2 2026. In terms of finances, cash reserves have increased to $128.7 million, net income has risen to $22.4 million, and the company’s runway is expected to extend into the second half of 2028.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies targeting oncogenic mutations, with a focus on brain-penetrant EGFR inhibitors for NSCLC and glioblastoma.